Interpace Biosciences (IDXG) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	3 Months Ended
	Mar. 31, 2014	2-May-14
Entity Information [Line Items]	'	'
Entity Registrant Name	'PDI INC	'
Entity Central Index Key	'0001054102	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	15,322,318

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheet (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$37,878	$45,639
Short-term investments	103	103
Accounts receivable, net	8,471	2,422
Unbilled costs and accrued profits on contracts in progress	5,558	7,982
Other current assets	6,999	6,563
Total current assets	59,009	62,709
Property and equipment, net	2,846	2,789
Goodwill	2,523	2,523
Other long-term assets	1,004	1,043
Total assets	65,382	69,064
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable	2,493	2,350
Unearned contract revenue	8,785	9,379
Accrued salary and bonus	7,163	9,643
Other accrued expenses	10,863	10,028
Total current liabilities	29,304	31,400
Long-term liabilities	4,736	5,185
Total liabilities	34,040	36,585
Commitments and contingencies (Note 7)	'	'
Stockholders’ equity:	'	'
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.01 par value; 40,000,000 shares authorized; 16,512,332 and 16,316,169 shares issued, respectively; 15,332,318 and 15,169,898 shares outstanding, respectively	165	163
Additional paid-in capital	130,917	130,229
Accumulated deficit	-85,435	-83,823
Accumulated other comprehensive income	16	16
Treasury stock, at cost (1,190,014 and 1,146,271 shares, respectively)	-14,321	-14,106
Total stockholders' equity	31,342	32,479
Total liabilities and stockholders' equity	$65,382	$69,064

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheet (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred Stock, Par Value	$0.01	$0.01
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$0.01	$0.01
Common Stock, Shares Authorized	40,000,000	40,000,000
Common Stock, Shares, Issued	16,512,332	16,316,169
Common Stock, Shares, Outstanding	15,322,318	15,169,898
Treasury Stock, Shares	1,190,014	1,146,271

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue, net	$32,778	$42,923
Cost of services	27,669	34,450
Gross profit	5,109	8,473
Compensation expense	3,541	4,155
Other selling, general and administrative expenses	3,065	2,065
Total operating expenses	6,606	6,220
Operating (loss) income	-1,497	2,253
Other expense, net	-17	-9
(Loss) income from continuing operations before income tax	-1,514	2,244
Provision (benefit) for income tax	66	64
(Loss) income from continuing operations	-1,580	2,180
(Loss) income from discontinued operations, net of tax	-32	-54
Net (loss) income	-1,612	2,126
Other Comprehensive Income (Loss)	'	'
Unrealized holding gain (loss) on available-for-sale securities, net	0	0
Comprehensive income (loss)	($1,612)	$2,126
Basic and diluted (loss) income per share of common stock from:	'	'
Income (Loss) from Continuing Operations, Per Basic Share	($0.11)	$0.15
Income (Loss) from Discontinued Operations, Net of Tax, Per Basic Share	$0	($0.01)
Net Income (loss) per basic and diluted share of common stock	($0.11)	$0.14
Continuing operations	($0.11)	$0.14
Discontinued operations	$0	$0
Net income (loss) per diluted share of common stock	($0.11)	$0.14
Weighted average number of common shares and common share equivalents outstanding:	'	'
Basic	14,760	14,983
Diluted	14,760	15,074

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net income (loss)	($1,612)	$2,126
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation and amortization	457	288
Realignment accrual accretion	35	35
Stock-based compensation	690	351
Other changes in assets and liabilities:	'	'
Decrease in accounts receivable	-6,049	1,140
Increase in unbilled costs	2,424	-5,113
Decrease (increase) in other current assets	32	330
Decrease in other long-term assets	140	0
Increase (decrease) in accounts payable	143	690
(Decrease) increase in unearned contract revenue	-594	-626
Increase (decrease) in accrued salaries and bonus	-2,480	1,143
Increase (decrease) in other accrued expenses	835	1,128
Decrease in long-term liabilities	-484	-270
Net cash provided by (used in) operating activities	-6,463	1,222
Cash Flows From Investing Activities	'	'
Purchase of property and equipment	-514	-445
Payments for (Proceeds from) Loans and Leases	-569	0
Net cash used in investing activities	-1,083	-445
Cash Flows From Financing Activities	'	'
Payments for Repurchase of Common Stock	-215	-227
Net cash used in financing activities	-215	-227
Net increase (decrease) in cash and cash equivalents	-7,761	550
Cash and cash equivalents – beginning	45,639	52,783
Cash and cash equivalents – ending	$37,878	$53,333

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation [Text Block]	'
	BASIS OF PRESENTATION
	The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of PDI, Inc. and its subsidiaries (the Company or PDI) and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the Securities and Exchange Commission (SEC) on March 6, 2014.  The interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  The interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements.  All significant intercompany balances and transactions have been eliminated in consolidation.  Operating results for the three-month period ended March 31, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies [Text Block]	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Accounting Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.
	Basic and Diluted Net Loss per Share
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted (loss) income per share for the three-month periods ended March 31, 2014 and 2013 is as follows:
		Three Months Ended
		March 31,
		2014		2013
	Basic weighted average number of common shares	14,760		14,983
	Dilutive effect of stock-based awards	—		91
	Diluted weighted average number of common shares	14,760		15,074
	The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:
		Three Months Ended
		March 31,
		2014	2013
	Options	43	50
	Stock-settled stock appreciation rights (SARs)	1,238	314
	Restricted stock/units	754	91
	Market contingent SARs	188	280
		2,223	735
	Goodwill and Other Intangible Assets
	The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of goodwill and other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the goodwill.
	The Company tests goodwill and indefinite lived intangible assets for impairment at least annually (as of December 31) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others: a significant decline in expected future cash flows; a sustained, significant decline in stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the pharmaceutical industry; unanticipated competition; and slower growth rates. Any adverse change in these factors could have a significant impact on the recoverability of goodwill and our consolidated financial results. At March 31, 2014, no indicators of impairment were identified.

Investments_in_Marketable_Secu

Investments in Marketable Securities	3 Months Ended
	Mar. 31, 2014
Marketable Securities [Abstract]	'
Investments in Marketable Securities [Text Block]	'
	INVESTMENTS IN MARKETABLE SECURITIES
	Available-for-sale securities are carried at fair value with the unrealized holding gains or losses, net of tax, included as a component of accumulated other comprehensive income (loss) in stockholders’ equity. Realized gains and losses on available-for-sale securities are computed based upon specific identification and included in other income (expense), net in the consolidated statement of operations.  Declines in value judged to be other-than-temporary on available-for-sale securities are recorded in other income (expense), net in the consolidated statement of operations and the cost basis of the security is reduced. The fair values for marketable equity securities are based on quoted market prices.  Held-to-maturity investments are stated at amortized cost which approximates fair value.  Interest income is accrued as earned.  Realized gains and losses on held-to-maturity investments are computed based upon specific identification and included in other income (expense), net in the condensed consolidated statement of comprehensive (loss) income.  The Company does not have any investments classified as trading.
	Available-for-sale securities consist of assets in a rabbi trust associated with the Company’s deferred compensation plan.  As of both March 31, 2014 and December 31, 2013, the carrying value of available-for-sale securities was approximately $103,000 and is included in short-term investments.  Available-for-sale securities as of both March 31, 2014 and December 31, 2013 consisted of approximately $55,000 in mutual funds and approximately $48,000 in money market accounts.
	The Company’s other marketable securities consist of investment grade debt instruments such as obligations of U.S. Treasury and U.S. Federal Government agencies.  These investments are categorized as held-to-maturity since the Company’s management has the ability and intent to hold these securities to maturity.  The Company’s held-to-maturity investments are carried at amortized cost which approximates fair value and are maintained in separate accounts to support the Company’s letters of credit.  The Company had standby letters of credit of approximately $2.0 million as of both March 31, 2014 and December 31, 2013, as collateral for its existing insurance policies and facility leases.
	At March 31, 2014 and December 31, 2013, held-to-maturity investments included the following:
				Maturing						Maturing
		March 31,		within		after 1 year		December 31,		within		after 1 year
		2014		1 year		through		2013		1 year		through
						3 years						3 years
	Cash/money accounts	$	135	$	135	$	—	$	116	$	116	$	—
	US Treasury securities	1,477		636		841		1,730		1,360		370
	Government agency securities	623		476		147		382		382		—
	Total	$	2,235	$	1,247	$	988	$	2,228	$	1,858	$	370
	At March 31, 2014 and December 31, 2013, held-to-maturity investments were recorded in the following accounts:
		March 31,		December 31,
		2014		2013
	Other current assets	$	1,247	$	1,858
	Other long-term assets	988		370
	Total	$	2,235	$	2,228

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets [Text Block]	'
	GOODWILL
	Goodwill recorded as of March 31, 2014 is attributable to the 2010 acquisition of Group DCA.  As of March 31, 2014 and December 31, 2013, the carrying amount of goodwill for Group DCA was $2.5 million.

Facilities_Realignment

Facilities Realignment	3 Months Ended
	Mar. 31, 2014
FACILITIES REALIGNMENT [Abstract]	'
Facilities Realignment [Text Block]	'
	FACILITIES REALIGNMENT
	The following table presents a rollforward of the Company’s restructuring reserve from December 31, 2013 to March 31, 2014, of which approximately $1.1 million is included in other accrued expenses and $0.6 million is included in long-term liabilities as of March 31, 2014. The Company recognizes accretion expense in Other expense, net in the Condensed Consolidated Statement of Comprehensive (Loss) Income.
		Sales			Marketing			Discontinued Operations			Total
		Services			Services
	Balance as of December 31, 2013	$	1,125		$	458		$	379		$	1,962
	Accretion	27			—			8			35
	Adjustments	—			(16		)	—			(16		)
	Payments	(168		)	(36		)	(53		)	(257		)
	Balance as of March 31, 2014	$	984		$	406		$	334		$	1,724

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements [Text Block]	'
	FAIR VALUE MEASUREMENTS
	The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:
	Level 1:	Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.
	Level 2:	Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.
	Level 3:	Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.
	In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.
		As of March 31, 2014				Fair Value Measurements
		Carrying		Fair		As of March 31, 2014
		Amount		Value		Level 1		Level 2		Level 3
	Assets:
	Cash and cash equivalents:
	Cash	$	8,557	$	8,557	$	8,557	$	—	$	—
	Money Market Funds	29,321		29,321		29,321		—		—
	Total	$	37,878	$	37,878	$	37,878	$	—	$	—
	Marketable securities:
	Money Market Funds	$	48	$	48	$	48	$	—	$	—
	Mutual Funds	55		55		55		—		—
	U.S. Treasury securities	1,477		1,477		1,477		—		—
	Government agency securities	623		623		623		—		—
	Total	$	2,203	$	2,203	$	2,203	$	—	$	—
	The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of March 31, 2014, the Company did not have any marketable securities in less active markets (level 2) or without observable market values that would require a high level of judgment to determine fair value (level 3).
	The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies [Text Block]	'
	COMMITMENTS AND CONTINGENCIES
	Letters of Credit
	As of March 31, 2014, the Company had outstanding letters of credit of $2.0 million as required by its existing insurance policies and facility leases.  These letters of credit are supported by investments in held-to-maturity securities.  See Note 3, Investments in Marketable Securities, for additional detail regarding investments in marketable securities.
	Litigation
	Due to the nature of the businesses in which the Company is engaged, such as product detailing and in the past, the distribution of products, it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or distributes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products, including pharmaceuticals. The Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.
	The Company routinely assesses its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. As of March 31, 2014, the Company's accrual for litigation and threatened litigation was not material to the consolidated financial statements.

Accrued_Expenses_and_LongTerm_

Accrued Expenses and Long-Term Liabilities	3 Months Ended
	Mar. 31, 2014
Other Liabilities Disclosure [Abstract]	'
Long-Term Liabilities [Text Block]	'
	ACCRUED EXPENSES AND LONG-TERM LIABILITIES
	Other accrued expenses consisted of the following as of March 31, 2014 and December 31, 2013:
		March 31, 2014		31-Dec-13
	Accrued pass-through costs	$	2,397	$	2,089
	Accrued reorganization expense	1,124		997
	Self insurance accruals	496		1,020
	Indemnification liability	875		875
	All others	5,971		5,047
		$	10,863	$	10,028
	Long-term liabilities consisted of the following as of March 31, 2014 and December 31, 2013:
		March 31, 2014		31-Dec-13
	Rent payable	$	846	$	969
	Uncertain tax positions	3,148		3,109
	Restructuring	600		965
	Other	142		142
		$	4,736	$	5,185

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation [Text Block]	'
	STOCK-BASED COMPENSATION
	In February 2014, under the terms of the stockholder-approved PDI, Inc. 2004 Stock Award Incentive Plan (the 2004 Plan), the Compensation and Management Development Committee of the Board (the Compensation Committee) approved grants of restricted stock to certain executive officers and members of senior management of the Company. The full Board approved the portion of these grants made to the Company’s Chief Executive Officer.  As part of the Company's 2013 long-term incentive plan, these grants aggregated 173,990 shares of restricted stock issued with a weighted average grant date fair value of $5.12 per share and 489,846 SARs with a weighted average grant date fair value of $1.82.
	The grant date fair values of SARs awards are determined using a Black-Scholes pricing model.  Assumptions utilized in the model are evaluated and revised, as necessary, to reflect market conditions and experience. The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the three-month period ended March 31, 2014:
		Three Months Ended
		31-Mar-14
	Risk-free interest rate	0.69%
	Expected life	3.5 years
	Expected volatility	48.01%
	Dividend yield	—%
	The Company did not issue any SARs during the three months ended March 31, 2013. In February 2014, the Company’s chief executive officer was granted 188,165 market contingent SARs.  The market contingent SARs have an exercise price of $5.10, a five year term to expiration, and a weighted-average fair value of $1.87.  The fair value estimate of the market contingent SARs was calculated using a Monte Carlo Simulation model.  The market contingent SARs are subject to a time-based vesting schedule, but will not vest unless and until certain additional, market-based conditions are satisfied: (1) with respect to the initial 36,496 market contingent SARs, which vest on a time-based schedule on the first anniversary of the date of grant, the closing price of the Company’s common stock is at least $7.65 per share for the average of 60 consecutive trading days anytime within five years from the grant date; (2) with respect to the next 64,460 market contingent SARs, which vest on a time-based schedule on the second anniversary of the date of grant, the closing price of the Company’s common stock is at least $10.20 per share for the average of 60 consecutive trading days anytime within five years from the grant date; and (3) with respect to the final 87,209 market contingent SARs, which vest on a time-based schedule on the third anniversary of the date of grant, the closing price of the Company’s common stock is at least $15.30 per share for the average of 60 consecutive trading days anytime within five years from the grant date.  These stock prices represent premiums in excess of at least 50% of the closing stock price of the Company’s common stock on the date of grant.
	The Company recognized $0.7 million and $0.4 million of stock-based compensation expense during each of the three-month periods ended March 31, 2014 and 2013, respectively.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes [Text Block]	'
	INCOME TAXES
	Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.  As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction.  The following table summarizes income tax expense on (loss) income from continuing operations and the effective tax rate for the three-month periods ended March 31, 2014 and 2013:
		Three Months Ended
		March 31,
		2014			2013
	Provision for income tax	$	66		$	64
	Effective income tax rate	(4.4		)%	2.9		%
	Income tax expense for each of the three-month periods ended March 31, 2014 and 2013 was primarily due to state taxes.

Segment_Information

Segment Information	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segment Information [Text Block]	'
	SEGMENT INFORMATION
	The accounting policies of the segments are described in Note 1 of the Company’s audited consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2013.  Corporate charges are allocated to each of the reporting segments on the basis of total salary expense. Corporate charges include corporate headquarters costs and certain depreciation expenses. Certain corporate capital expenditures have not been allocated from the Sales Services segment to the other reporting segments since it is impracticable to do so.
		Sales		Marketing			Product Commercialization Services			Consolidated
		Services		Services
	Three months ended March 31, 2014:
	Revenue	$	28,795	$	1,003		$	2,980		$	32,778
	Operating income (loss)	$	50	$	(1,323	)	$	(224	)	$	(1,497	)
	Capital expenditures	$	514	$	—		$	—		$	514
	Depreciation expense	$	207	$	229		$	21		$	457
	Three months ended March 31, 2013:
	Revenue	$	38,225	$	1,541		$	3,157		$	42,923
	Operating income (loss)	$	2,364	$	(683	)	$	572		$	2,253
	Capital expenditures	$	169	$	276		$	—		$	445
	Depreciation expense	$	234	$	51		$	3		$	288

Discontinued_Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations [Text Block]	'
	DISCONTINUED OPERATIONS
	On December 29, 2011 the Company entered into an agreement to sell certain assets of our Pharmakon business unit to Informed Medical Communications, Inc. (“Informed”) in exchange for potential future royalty payments and an ownership interest in Informed. In the fourth quarter of 2012, the Company wrote-off all of the assets related to the sale of Pharmakon to Informed as it believes that these assets have become impaired. On July 19, 2010, the Board approved closing the TVG business unit. The Company notified employees and issued a press release announcing this decision on July 20, 2010. The Consolidated Statements of Comprehensive Loss (Income) reflect the presentation of Pharmakon and TVG as discontinued operations in all periods presented.
	The table below presents the significant components of Pharmakon's and TVG’s results included in Loss from discontinued operations in the Condensed Consolidated Statements of Comprehensive Income (Loss) for the three-month periods ended March 31, 2014 and 2013.
		Three Months Ended
		March 31,
		2014			2013
	Revenue, net	$	—		$	—
	Loss from discontinued operations, before income tax	(31		)	(53		)
	Provision for income tax	1			1
	Loss from discontinued operations, net of tax	$	(32	)	$	(54	)
	The major classes of assets and liabilities included in the Condensed Consolidated Balance Sheets for TVG and Pharmakon as of March 31, 2014 and December 31, 2013 are as follows:
		March 31,			December 31,
		2014			2013
	Current assets	$	—		$	—
	Non-current assets	150			150
	Total assets	$	150		$	150
	Current liabilities	$	424		$	405
	Non-current liabilities	540			619
	Total liabilities	$	964		$	1,024

Investment_in_NonControlled_En

Investment in Non-Controlled Entity and Other Arrangements (Notes)	3 Months Ended
	Mar. 31, 2014
Investment and Loan With Non-Controllable Entity [Abstract]	'
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	'
	INVESTMENT IN NON-CONTROLLED ENTITY AND OTHER ARRANGEMENTS
	In August 2013, PDI entered into phase one of a collaboration agreement with a privately held molecular diagnostics company (the Diagnostics Company) to commercialize its fully-developed, molecular diagnostic tests. Under the terms of phase one of the collaboration agreement, PDI paid an initial fee of $1.5 million and has the ability to enter the second phase of the collaboration agreement in the form of a call option to purchase the outstanding common stock of the Diagnostics Company. PDI has recorded the initial fee as an investment in a non-controlled entity within Other current assets in the Consolidated Balance Sheets in accordance with ASC 325-20 Investments Other - Cost Method Investments.
	The Company also has the option to contribute an additional $0.5 million for mutually agreed upon activities in furtherance of collaboration efforts. The option price is dependent on the achievement of certain milestones during the collaboration period (the period up to the exercise of the purchase option or termination of the collaboration agreement) and could be up to $6.0 million if all milestones are achieved at their maximum levels. PDI can terminate the collaboration agreement if all milestones are not achieved by August 2014 and would receive a $1.0 million termination fee, leaving the Company with a maximum exposure of $0.5 million plus amounts contributed in furtherance of collaboration efforts.
	If all milestones are achieved by August 2014 and PDI has not exercised its option, the Diagnostics Company can require PDI to exercise the option to purchase its outstanding common stock or terminate the collaboration agreement and pay PDI a termination fee of approximately $2.0 million. If PDI purchases the outstanding common stock of the Diagnostics Company, in addition to the option price based on the achievement of milestones, beginning in 2015, PDI would pay a royalty of 7% on annual net revenue up to $50.0 million with escalating royalty percentages for higher annual net revenue capped at 11% for annual net revenue in excess of $100.0 million.
	During the period ended March 31, 2014, PDI loaned the Diagnostics Company approximately $0.6 million for the acquisition of a CLIA approved lab bearing a 4% interest rate. This loan is secured by the lab and the assets of the lab and is payable to PDI at the sooner of: May 31, 2015; the expiration or termination of the collaboration agreement between the parties; the acquisition of the Diagnostics Company by PDI; or default by the Diagnostics Company. PDI has recorded the loan receivable within Other current assets in the Consolidated Balance Sheets.
	Other Arrangements
	In October 2013, the Company entered into phase one of a collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by Transgenomic, in the United States. Under the terms of the strategic collaboration agreement, PDI will be responsible for all U.S.-based marketing and promotion of CardioPredict™, while Transgenomic will be responsible for processing CardioPredict™ in its state-of-the-art CLIA lab and all customer support. Both parties will pay their respective expenses and will split profit on a formula basis. If the Company moves to the second phase of the collaboration agreement, PDI may provide Transgenomic with funding support of up to $3.0 million, principally to finance working capital requirements for the product. Through March 31, 2014, the Company has not provided any funding to Transgenomic.
	PDI's costs related to both of these agreements are expensed in the Company's PC Services segment and reflected in Cost of sales or Selling, general and administrative expenses in the Consolidated Statement of Comprehensive Loss, depending upon the underlying nature of the expenses incurred.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Accounting Policies [Abstract]	'	'
Accounting Estimates [Policy Text Block]	'	'
		Accounting Estimates
Goodwill and Other Intangible Assets [Policy Text Block]	'	'
	Goodwill and Other Intangible Assets
	The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of goodwill and other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the goodwill.
	The Company tests goodwill and indefinite lived intangible assets for impairment at least annually (as of December 31) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others: a significant decline in expected future cash flows; a sustained, significant decline in stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the pharmaceutical industry; unanticipated competition; and slower growth rates. Any adverse change in these factors could have a significant impact on the recoverability of goodwill and our consolidated financial results. At March 31, 2014, no indicators of impairment were identified.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Weighted Average Number of Shares [Table Text Block]	'
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted (loss) income per share for the three-month periods ended March 31, 2014 and 2013 is as follows:
		Three Months Ended
		March 31,
		2014		2013
	Basic weighted average number of common shares	14,760		14,983
	Dilutive effect of stock-based awards	—		91
	Diluted weighted average number of common shares	14,760		15,074
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:
		Three Months Ended
		March 31,
		2014	2013
	Options	43	50
	Stock-settled stock appreciation rights (SARs)	1,238	314
	Restricted stock/units	754	91
	Market contingent SARs	188	280
		2,223	735

Investments_in_Marketable_Secu1

Investments in Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2014
Marketable Securities [Abstract]	'
Investments Classified by Contractual Maturity Date [Table Text Block]	'
	At March 31, 2014 and December 31, 2013, held-to-maturity investments included the following:
				Maturing						Maturing
		March 31,		within		after 1 year		December 31,		within		after 1 year
		2014		1 year		through		2013		1 year		through
						3 years						3 years
	Cash/money accounts	$	135	$	135	$	—	$	116	$	116	$	—
	US Treasury securities	1,477		636		841		1,730		1,360		370
	Government agency securities	623		476		147		382		382		—
	Total	$	2,235	$	1,247	$	988	$	2,228	$	1,858	$	370
Held-to-maturity Securities [Table Text Block]	'
	At March 31, 2014 and December 31, 2013, held-to-maturity investments were recorded in the following accounts:
		March 31,		December 31,
		2014		2013
	Other current assets	$	1,247	$	1,858
	Other long-term assets	988		370
	Total	$	2,235	$	2,228

Facilities_Realignment_Tables

Facilities Realignment (Tables)	3 Months Ended
	Mar. 31, 2014
FACILITIES REALIGNMENT [Abstract]	'
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	'
	The following table presents a rollforward of the Company’s restructuring reserve from December 31, 2013 to March 31, 2014, of which approximately $1.1 million is included in other accrued expenses and $0.6 million is included in long-term liabilities as of March 31, 2014. The Company recognizes accretion expense in Other expense, net in the Condensed Consolidated Statement of Comprehensive (Loss) Income.
		Sales			Marketing			Discontinued Operations			Total
		Services			Services
	Balance as of December 31, 2013	$	1,125		$	458		$	379		$	1,962
	Accretion	27			—			8			35
	Adjustments	—			(16		)	—			(16		)
	Payments	(168		)	(36		)	(53		)	(257		)
	Balance as of March 31, 2014	$	984		$	406		$	334		$	1,724

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
		As of March 31, 2014				Fair Value Measurements
		Carrying		Fair		As of March 31, 2014
		Amount		Value		Level 1		Level 2		Level 3
	Assets:
	Cash and cash equivalents:
	Cash	$	8,557	$	8,557	$	8,557	$	—	$	—
	Money Market Funds	29,321		29,321		29,321		—		—
	Total	$	37,878	$	37,878	$	37,878	$	—	$	—
	Marketable securities:
	Money Market Funds	$	48	$	48	$	48	$	—	$	—
	Mutual Funds	55		55		55		—		—
	U.S. Treasury securities	1,477		1,477		1,477		—		—
	Government agency securities	623		623		623		—		—
	Total	$	2,203	$	2,203	$	2,203	$	—	$	—

Accrued_Expenses_and_LongTerm_1

Accrued Expenses and Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Other Liabilities Disclosure [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Other accrued expenses consisted of the following as of March 31, 2014 and December 31, 2013:
		March 31, 2014		31-Dec-13
	Accrued pass-through costs	$	2,397	$	2,089
	Accrued reorganization expense	1,124		997
	Self insurance accruals	496		1,020
	Indemnification liability	875		875
	All others	5,971		5,047
		$	10,863	$	10,028
Long-term Liabilities [Table Text Block]	'
	Long-term liabilities consisted of the following as of March 31, 2014 and December 31, 2013:
		March 31, 2014		31-Dec-13
	Rent payable	$	846	$	969
	Uncertain tax positions	3,148		3,109
	Restructuring	600		965
	Other	142		142
		$	4,736	$	5,185

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The following table provides the weighted average assumptions used in determining the fair value of the non-market based SARs awards granted during the three-month period ended March 31, 2014:
		Three Months Ended
		31-Mar-14
	Risk-free interest rate	0.69%
	Expected life	3.5 years
	Expected volatility	48.01%
	Dividend yield	—%

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The following table summarizes income tax expense on (loss) income from continuing operations and the effective tax rate for the three-month periods ended March 31, 2014 and 2013:
		Three Months Ended
		March 31,
		2014			2013
	Provision for income tax	$	66		$	64
	Effective income tax rate	(4.4		)%	2.9		%

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
		Sales		Marketing			Product Commercialization Services			Consolidated
		Services		Services
	Three months ended March 31, 2014:
	Revenue	$	28,795	$	1,003		$	2,980		$	32,778
	Operating income (loss)	$	50	$	(1,323	)	$	(224	)	$	(1,497	)
	Capital expenditures	$	514	$	—		$	—		$	514
	Depreciation expense	$	207	$	229		$	21		$	457
	Three months ended March 31, 2013:
	Revenue	$	38,225	$	1,541		$	3,157		$	42,923
	Operating income (loss)	$	2,364	$	(683	)	$	572		$	2,253
	Capital expenditures	$	169	$	276		$	—		$	445
	Depreciation expense	$	234	$	51		$	3		$	288

Discontinued_Operations_Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
		March 31,			December 31,
		2014			2013
	Current assets	$	—		$	—
	Non-current assets	150			150
	Total assets	$	150		$	150
	Current liabilities	$	424		$	405
	Non-current liabilities	540			619
	Total liabilities	$	964		$	1,024
		Three Months Ended
		March 31,
		2014			2013
	Revenue, net	$	—		$	—
	Loss from discontinued operations, before income tax	(31		)	(53		)
	Provision for income tax	1			1
	Loss from discontinued operations, net of tax	$	(32	)	$	(54	)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Shares outstanding) (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Accounting Policies [Abstract]	'	'
Basic weighted average number of common shares	14,760	14,983
Dilutive effect of stock-based awards	0	91
Diluted weighted average number of common shares	14,760	15,074

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Anti-dilutive shares) (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Weighted Average Number Diluted Shares Outstanding Adjustment	0	91
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,223	735
Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	43	50
Stock-settled stock appreciation rights (SARs) [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,238	314
Restricted stock/units [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	754	91
Performance contingent SARs [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	188	280

Investments_in_Marketable_Secu2

Investments in Marketable Securities (Held to Maturity Securities, by Maturity) (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Schedule of Held-to-maturity Securities [Line Items]	'	'
Available-for-sale Securities	$103,000	$103,000
Letters of Credit Outstanding, Amount	2,000,000	'
Held-to-maturity Securities, Current	1,247,000	1,858,000
Held-to-maturity Securities, Noncurrent	988,000	370,000
Held-to-maturity Securities, Total	2,235,000	2,228,000
Mutual Funds [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Available-for-sale Securities	55,000	55,000
Cash/Money Market Accounts [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Available-for-sale Securities	48,000	48,000
Held-to-maturity Securities, Current	135,000	116,000
Held-to-maturity Securities, Noncurrent	0	0
Held-to-maturity Securities, Total	135,000	116,000
US Treasury Securities [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Held-to-maturity Securities, Current	636,000	1,360,000
Held-to-maturity Securities, Noncurrent	841,000	370,000
Held-to-maturity Securities, Total	1,477,000	1,730,000
US Government Agencies Securities [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Held-to-maturity Securities, Current	476,000	382,000
Held-to-maturity Securities, Noncurrent	147,000	0
Held-to-maturity Securities, Total	$623,000	$382,000

Goodwill_Details

Goodwill (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Goodwill	$2,523	$2,523

Facilities_Realignment_Details

Facilities Realignment (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring Reserve, Current	$1,124	'	$997
Restructuring Reserve, Noncurrent	600	'	965
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, Balance as of December 31, 2012	1,962	'	'
Accretion	35	35	'
Adjustments	-16	'	'
Payments	-257	'	'
Restructuring Reserve, Balance as of March 31, 2013	1,724	'	'
Sales Services [Member]	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, Balance as of December 31, 2012	1,125	'	'
Accretion	27	'	'
Adjustments	0	'	'
Payments	-168	'	'
Restructuring Reserve, Balance as of March 31, 2013	984	'	'
Marketing Services [Member]	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, Balance as of December 31, 2012	458	'	'
Accretion	0	'	'
Adjustments	-16	'	'
Payments	36	'	'
Restructuring Reserve, Balance as of March 31, 2013	406	'	'
Segment, Discontinued Operations [Member]	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, Balance as of December 31, 2012	379	'	'
Accretion	8	'	'
Adjustments	0	'	'
Payments	-53	'	'
Restructuring Reserve, Balance as of March 31, 2013	$334	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Available-for-sale Securities	$103,000	$103,000
Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	37,878,000	'
Marketable Securities, Fair Value Disclosure	2,203,000	'
Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	37,878,000	'
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	37,878,000	'
Marketable Securities, Fair Value Disclosure	2,203,000	'
Money Market Funds [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48,000	'
Money Market Funds [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48,000	'
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48,000	'
Mutual Funds [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	55,000	'
Mutual Funds [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	55,000	'
Mutual Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	55,000	'
US Treasury Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	1,477,000	'
US Treasury Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	1,477,000	'
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	1,477,000	'
US Government Agencies Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	623,000	'
US Government Agencies Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	623,000	'
US Government Agencies Securities [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	623,000	'
Cash [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	8,557,000	'
Cash [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	8,557,000	'
Cash [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	8,557,000	'
Money Market Funds [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	29,321,000	'
Money Market Funds [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	29,321,000	'
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$29,321,000	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
Letters of Credit Outstanding, Amount	$2

Accrued_Expenses_and_LongTerm_2

Accrued Expenses and Long-Term Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'	'
Other Liabilities	$2,397	$2,089
Rent Payable	846	969
Uncertain Tax Positions	3,148	3,109
Restructuring	600	965
Other	142	142
Total Long-Term Liabilities	4,736	5,185
Restructuring Reserve, Current	1,124	997
Self Insurance Reserve, Current	496	1,020
Liability for Uncertain Tax Positions, Current	875	875
Other Accrued Liabilities, Current	5,971	5,047
Accrued Liabilities, Current	$10,863	$10,028

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free Interest Rate	0.69%	'
Expected life (in years)	'3 years 6 months	'
Expected volatility	48.01%	'
Dividend Yield	0.00%	'
Stock-based Compensation Expense	$690	$351
Management [Member] | Restricted Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock Issued	173,990	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$5.12	'
Management [Member] | Stock Appreciation Rights (SARs) [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock Issued	489,846	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$1.82	'
Chief Executive Officer [Member] | Performance base shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	188,165	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$5.10	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$1.87	'
Expected life (in years)	'5 years	'
Performance Shares Target Premium	50.00%	'
Consecutive trading days	'60 days	'
Performance Shares First Tranche [Domain] | Chief Executive Officer [Member] | Performance base shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Performance shares available for exercise	36,496	'
Average stock price, performance shares	$7.65	'
Performance Shares Second Tranche [Domain] | Chief Executive Officer [Member] | Performance base shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life (in years)	'5 years	'
Performance shares available for exercise	64,460	'
Average stock price, performance shares	$10.20	'
Performance Shares Final Tranche [Domain] | Chief Executive Officer [Member] | Performance base shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life (in years)	'5 years	'
Performance shares available for exercise	87,209	'
Average stock price, performance shares	$15.30	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	-4.40%	2.90%
Provision (benefit) for income tax	$66	$64

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Revenues	$32,778	$42,923
Operating (loss) income	-1,497	2,253
Capital expenditures	514	445
Depreciation expense	457	288
Sales Services [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues	28,795	38,225
Operating (loss) income	50	2,364
Capital expenditures	514	169
Depreciation expense	207	234
Marketing Services [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues	1,003	1,541
Operating (loss) income	-1,323	-683
Capital expenditures	0	276
Depreciation expense	229	51
Product Commercialization Services [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues	2,980	3,157
Operating (loss) income	-224	572
Capital expenditures	0	0
Depreciation expense	$21	$3

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]	'	'	'
Revenue, net	$0	$0	'
(Loss) income from discontinued operations, before income tax	-31	-53	'
Provision (benefit) for income tax	1	1	'
(Loss) income from discontinued operations, net of tax	-32	-54	'
Current assets	0	'	0
Non-current assets	150	'	150
Total assets	150	'	150
Current liabilities	424	'	405
Non-current liabilities	540	'	619
Total liabilities	$964	'	$1,024

Investment_in_NonControlled_En1

Investment in Non-Controlled Entity and Other Arrangements (Details) (USD $)	12 Months Ended		24 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2013
Investment and Loan With Non-Controllable Entity [Abstract]	'	'	'	'
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures	'	'	'	$1.50
Other Significant Noncash Transaction, Value of Consideration Given	'	0.5	'	'
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	'	'	'	6
Business Combination, Indemnification Assets, Range of Outcomes, Value, Low	'	1	'	'
Loss Contingency, Range of Possible Loss, Minimum	'	0.5	'	'
Business Combination, Indemnification Assets, Range of Outcomes, Value, High	'	2	'	'
Royalty Percentage, Minimum Range	7.00%	'	'	'
Revenue Range, Low-end	50	'	'	'
Royalty Percentage, Maximum Range	11.00%	'	'	'
Revenue Range Maximum	100	'	'	'
Payments for (Proceeds from) Deposit on Loan	'	0.6	'	'
Debt Instrument, Interest Rate During Period	'	4.00%	'	'
Effect on Future Cash Flows, Amount	'	'	$3	'